Cargando…

Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors

BACKGROUND: Chiauranib is a novel orally active multi-target inhibitor that simultaneously inhibits the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRα, and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R. This phase I dose-escalation study was to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Yongkun, Yang, Lin, Hao, Xuezhi, Liu, Yutao, Zhang, Jinwen, Ning, Zhiqiang, Shi, Yuankai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332596/ https://www.ncbi.nlm.nih.gov/pubmed/30642372 http://dx.doi.org/10.1186/s13045-018-0695-0

Ejemplares similares

Inhibition of extranodal NK/T-cell lymphoma by Chiauranib through an AIF-dependent pathway and its synergy with L-asparaginase
por: Gao, Tianxiao, et al.
Publicado: (2023)

Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
por: Cao, Junning, et al.
Publicado: (2017)

Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
por: Tsai, Hui-Jen, et al.
Publicado: (2021)

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib
por: Koyama, Noriyuki, et al.
Publicado: (2014)

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
por: Naing, Aung, et al.
Publicado: (2013)

Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway
por: Tang, Yuanfang, et al.
Publicado: (2022)

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours
por: Strumberg, D, et al.
Publicado: (2008)

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
por: Padda, Sukhmani K., et al.
Publicado: (2011)

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
por: Robert, Francisco, et al.
Publicado: (2009)

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
por: Freyer, G, et al.
Publicado: (2012)

Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors
por: Esaki, Taito, et al.
Publicado: (2019)

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
por: Harding, James J., et al.
Publicado: (2021)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2014)

Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
por: Li, Huiping, et al.
Publicado: (2020)

A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer
por: Chen, Justin A., et al.
Publicado: (2022)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors
por: Minami, Hironobu, et al.
Publicado: (2016)

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
por: LoRusso, Patricia M., et al.
Publicado: (2017)

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
por: Adjei, Alex A., et al.
Publicado: (2016)

Dose Escalation Methods in Phase I Cancer Clinical Trials
por: Le Tourneau, Christophe, et al.
Publicado: (2009)

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
por: Desai, Jayesh, et al.
Publicado: (2020)

Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients
por: Xu, Jianming, et al.
Publicado: (2023)

Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors
por: Naing, Aung, et al.
Publicado: (2011)

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
por: Diaz-Padilla, I, et al.
Publicado: (2012)

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study
por: Blais, Normand, et al.
Publicado: (2013)

Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies
por: Rixe, Olivier, et al.
Publicado: (2015)

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
por: Hong, D S, et al.
Publicado: (2019)

Neoadjuvant stereotactic radiosurgery for intracerebral metastases of solid tumors (NepoMUC): a phase I dose escalation trial
por: Diehl, Christian D., et al.
Publicado: (2019)

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia
por: van Tilburg, Cornelis M., et al.
Publicado: (2019)

The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
por: Yonemori, Kan, et al.
Publicado: (2021)

Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors
por: Nishikawa, Tadaaki, et al.
Publicado: (2017)

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
por: Berlin, Jordan, et al.
Publicado: (2018)

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
por: Papadatos-Pastos, Dionysis, et al.
Publicado: (2022)

Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors
por: Plummer, Ruth, et al.
Publicado: (2014)

Phase I Dose-Escalation Study of Nimustine in Tumor-Bearing Dogs
por: TAKAHASHI, Masashi, et al.
Publicado: (2014)

Phase I dose-escalation oncology trials with sequential multiple schedules
por: Günhan, Burak Kürsad, et al.
Publicado: (2021)

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
por: Desar, I M E, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_dfe56joct0a6sl7tj64ggnllu3